Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 3/20 | 0.55 |
| ▸ | CHRM1 known ✓ | P11229 | 3/20 | 0.55 |
| ▸ | CHRM5 known ✓ | P08912 | 2/20 | 0.47 |
| ▸ | CHRM3 known ✓ | P20309 | 2/20 | 0.47 |
| ▸ | HRH1 known ✓ | P35367 | 2/20 | 0.47 |
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.47 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.47 |
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.46 |
| ▸ | CHRM4 known ✓ | P08173 | 1/20 | 0.46 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.46 |
| ▸ | HRH2 known ✓ | P25021 | 1/20 | 0.46 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.46 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.46 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.46 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.46 |
| ▸ | KCNQ1 known ✓ | P51787 | 1/20 | 0.46 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.46 |
| ▸ | CACNA1C known ✓ | Q13936 | 1/20 | 0.46 |
| ▸ | SCN5A known ✓ | Q14524 | 1/20 | 0.46 |
| ▸ | KCND3 known ✓ | Q9UK17 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL597393 | 1.00 | CHRM2 (0.55) | CHRM2CHRM1CHRM5CHRM3HRH1 | |
| SCHEMBL723428 | 0.99 | CHRM2 (0.56) | CHRM2CHRM1CHRM5CHRM3HRH1 | |
| SCHEMBL1783715 | 0.99 | CHRM2 (0.56) | CHRM2CHRM1CHRM5CHRM3HRH1 | |
| SCHEMBL27773494 | 0.92 | CHRM2 (0.48) | CHRM2CHRM1CHRM5CHRM3HRH1 | |
| SCHEMBL27556305 | 0.92 | CHRM2 (0.48) | CHRM2CHRM1CHRM5CHRM3HRH1 | |
| SCHEMBL5179164 | 0.92 | CHRM2 (0.55) | CHRM2CHRM1CHRM5CHRM3HRH1 | |
| SCHEMBL5179157 | 0.92 | CHRM2 (0.55) | CHRM2CHRM1CHRM5CHRM3HRH1 | |
| SCHEMBL1354912 | 0.90 | CHRM2 (0.53) | CHRM2CHRM1CHRM5CHRM3HRH1 | |
| SCHEMBL1354913 | 0.90 | CHRM2 (0.53) | CHRM2CHRM1CHRM5CHRM3HRH1 | |
| SCHEMBL2599542 | 0.89 | CHRM2 (0.47) | CHRM2CHRM1CHRM5CHRM3HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9012678-B2 | Processes for the preparation of fesoterodine | CADILA HEALTHCARE LIMITED (IN) | 2015-04-21 | — | — | US | claimed |
| US-20130197260-A1 | PROCESSES FOR THE PREPARATION OF FESOTERODINE | CADILA HEALTHCARE LIMITED (IN) | 2013-08-01 | — | — | US | claimed |
| US-20100217034-A1 | Process for the Preparation of Fesoterodine | ACTAVIS GROUP PTC EHF (IS) | 2010-08-26 | — | — | US | claimed |
| WO-2009037569-A2 | AN IMPROVED PROCESS FOR THE PREPARATION OF FESOTERODINE | ACTAVIS GROUP PTC EHF (IS) | 2009-03-26 | — | — | WO | claimed |
| US-9012678-B2 | Processes for the preparation of fesoterodine | CADILA HEALTHCARE LIMITED (IN) | 2015-04-21 | — | — | US | disclosed |
| EP-1940774-B1 | NEW SYNTHESIS OF SUBSTITUTED HYDROXYMETHYL PHENOLS | SCHWARZ PHARMA LTD (IE) | 2014-03-05 | — | — | EP | disclosed |
| EP-2029523-B1 | ACCELERATED SYNTHESIS OF SUBSTITUTED HYDROXYMETHYL PHENOLS | SCHWARZ PHARMA LTD (IE) | 2013-08-21 | — | — | EP | disclosed |
| EP-2032522-B1 | SHORTENED SYNTHESIS USING PARAFORMALDEHYDE OR TRIOXANE | SCHWARZ PHARMA LTD (IE) | 2013-08-21 | — | — | EP | disclosed |
| US-20130197260-A1 | PROCESSES FOR THE PREPARATION OF FESOTERODINE | CADILA HEALTHCARE LIMITED (IN) | 2013-08-01 | — | — | US | disclosed |
| US-8344176-B2 | Synthesis of substituted hydroxymethyl phenols | SCHWARZ PHARMA LTD. (IE) | 2013-01-01 | — | — | US | disclosed |
| US-8299306-B2 | Accelerated synthesis of substituted hydroxymethyl phenols | UCB MANUFACTURING IRELAND LIMITED (IE) | 2012-10-30 | — | — | US | disclosed |
| WO-2012098560-A2 | PROCESS FOR THE PREPARATION OF MUSCARINIC RECEPTOR ANTAGONIST | MSN LABORATORIES LIMITED (IN) | 2012-07-26 | — | — | WO | disclosed |
| WO-2009044278-A1 | AMORPHOUS FESOTERODINE FUMARATE | ACTAVIS GROUP PTC EHF (IS) | 2009-04-09 | — | — | WO | disclosed |
| WO-2009037569-A2 | AN IMPROVED PROCESS FOR THE PREPARATION OF FESOTERODINE | ACTAVIS GROUP PTC EHF (IS) | 2009-03-26 | — | — | WO | disclosed |
| EP-2032522-A1 | SHORTENED SYNTHESIS USING PARAFORMALDEHYDE OR TRIOXANE | Schwarz Pharma Ltd. (IE) | 2009-03-11 | — | — | EP | disclosed |
| EP-2029523-A1 | ACCELERATED SYNTHESIS OF SUBSTITUTED HYDROXYMETHYL PHENOLS | Schwarz Pharma Ltd. (IE) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007144091-A1 | SHORTENED SYNTHESIS USING PARAFORMALDEHYDE OR TRIOXANE | SCHWARZ PHARMA LTD. (IE) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007140965-A1 | ACCELERATED SYNTHESIS OF SUBSTITUTED HYDROXYMETHYL PHENOLS | SCHWARZ PHARMA LTD. (IE) | 2007-12-13 | — | — | WO | disclosed |
| EP-1862449-A1 | A shortened synthesis of substituted hydroxymethyl phenols | Schwarz Pharma Ltd. (IE) | 2007-12-05 | — | — | EP | disclosed |
| US-6858650-B1 | For therapy of urinary incontinence | SCHWARZ PHARMA AG (DE) | 2005-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130197260-A1 | PROCESSES FOR THE PREPARATION OF FESOTERODINE | QDPR, FES, SULT1A1 | CHRM2 211/4885CHRM1 165/4885CHRM5 219/4885 |
| US-20100217034-A1 | Process for the Preparation of Fesoterodine | ADRB3, FES, QDPR | CHRM2 107/4885CHRM1 279/4885CHRM5 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.